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Abstract 
With the rapid increase in the elder population nationwide, the problem of 
excessive dependence on risky antipsychotic drug treatment for dementia-related 
behavioral problems in nursing facilities must be addressed.  At the federal level, 
the over-prescription of antipsychotics to the elderly in nursing homes is 
addressed first by regulation specific to nursing facilities, such as the Federal 
Nursing Home Reform Amendments (FNHRA), a part of the Ombudsman Budget 
Reconciliation Act of 1987 (OBRA ’87) as well as through the Centers for 
Medicare and Medicaid Services (CMS) guidelines.   Secondarily, the Food and 
Drug Administration (FDA) has authority to issue black box warnings and 
regulation pertaining to off-label drug use for antipsychotics used to treat 
behavioral problems associated with dementia, a use that has not been approved 
by the FDA.  Additionally, under state common law, these problems are 
addressed under the informed consent and right to refuse treatment doctrines. 
Despite the extensive multi-tiered body of law addressing this issue, no coherent 
and effective system has yet been devised to effectively protect patient rights. 
This paper suggests solutions to system failures via multi-faceted changes at 
federal and state levels in order to make the available framework more coherent 
and facilitate a shift to a nonpharmacologic treatment emphasis in the future.  
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I. Introduction 
By 2030, 70 million Americans will be over the age of 65, comprising more than 20% of the 
American population.
1  The number of residents in long term care services like nursing homes 
will increase from 8 million in 2000 to 19 million in 2050.
2  Mental disorders are present in a 
large percentage of the nursing home population.
3  Antipsychotics,
4  benzodiazepines, and 
antidepressants are among the medications most commonly used to manage problem behaviors.
5  
Historically, antipsychotics have been used excessively and without appropriate diagnosis or 
monitoring for side effects in nursing home residents, often solely for the convenience of staff.
6   
With the rapid increase in the elder population nationwide, problems specific to this age 
group have come to light and must be addressed.  Despite the multiplicity of strategies devised to 
address these issues, no approach has yet adequately resolved the situation. At the federal level, 
the over-prescription of antipsychotics to the elderly in nursing homes is addressed first by 
regulation specific to nursing facilities, such as the Federal Nursing Home Reform Amendments 
(FNHRA), a part of the Ombudsman Budget Reconciliation Act of 1987 (OBRA ’87) as well as  
                                                         
1 See Gregory Spencer, U.S. Dep’t of Commerce, Pub. No. P25-1130, Population Projections of the United States 
by Age, Sex, Race, and Hispanic Origin: 1995-2050, U.S. Bureau of the Census Consumer Population Reports 1, 10 
tbl.G (1996) available at http://www.census.gov/prod/l/pop/p25-1130.pdf.  As of 2006, there were 37 million 
Americans over the age of sixty-five.  Fed. Interagency Forum on Aging-Related Statistics, Older Americans 2008: 
Key Indicators of Well-Being 2 (2008), available at 
http://againgstats.gov/agingstatsdotnet/Main_Site/Data/2008_Douments/OA_2008.pdf. 
2 See Office of Assistant Sec’y for Planning & Evaluation, Dep’t of Health & Human Servs. et al., The Future 
Supply Long-Term Care Workers in Relation to the Aging Baby Boom Generation: Report to Congress 3 (2003), 
available at http://aspe.hhs.gov/daltcp/reports/ltcwork.pdf. 
3 See Pravin Kamble et al., Use of Antipsychotics Among Elderly Nursing Home Residents with Dementia in the US: 
An Analysis of National Survey Data, 26 DRUGS & AGING 483-492 (2009). 
4 Antipsychotic drugs, commonly referred to as psychotropic or neuroleptic, are often used for the treatment of 
severe mental disorders.  See Riese v. St. Mary’s Hosp. & Med. Ctr., 209 Cal. App. 3d 1303, 1310 (1987) (defining 
antipsychotic drugs). 
5 See Peter P. De Deyn, Risperidone for the Treatment of Neuropsychiatric Features in Dementia, 11 DRUGS & 
AGING 887-896 (2006). 
6 See Marcel G.M. Rikkert, Antipsychotics for Behavioural and Psychological Problems in Elderly People with 
Dementia: A Systematic Review of Adverse Events, 22 DRUGS & AGING 845-858(2005).   2 
through the Centers for Medicare and Medicaid Services (CMS)
7 guidelines.   Secondarily, the 
Food and Drug Administration (FDA) has authority to issue black box warnings and regulation 
pertaining to off-label drug use for antipsychotics used to treat behavioral problems associated 
with dementia, a use that has not been approved by the FDA.  Although this authority has been 
used primarily to target drug manufacturers, black box warnings and off-label drug use 
regulation could also be used to regulate further downstream in nursing facilities to stem the 
over-prescription of antipsychotics. Additionally, under state common law, these problems are 
addressed under the informed consent and right to refuse treatment doctrines, which include 
resident competence, knowledge, and voluntariness of medical treatment.  Despite this extensive 
multi-tiered body of law and the risky nature of this treatment option, no coherent and effective 
system has yet been devised to effectively protect patient rights.  
This paper will attempt to offer a way in which legislative, judicial, and policy considerations 
may work in tandem in order to create meaningful private rights of action for nursing home 
patients who have been overmedicated with antipsychotic drugs as an alternative to personal 
care. Part II addresses the complex medical issues of treating elderly nursing home residents with 
antipsychotic drugs for the symptoms of dementia in order to clarify the issue and create a 
background against which legal reform should be considered.  Part III summarizes current 
federal legislation addressing nursing home resident rights and the strengths and weaknesses of 
CMS guidelines and federal reform.  FDA regulation of off-label drugs and the issuance of 
black-box warnings will also be addressed, along with their relative success in litigation against 
pharmaceutical companies advertising antipsychotics for off-label use in nursing homes for 
dementia patients and the ways in which this mode of action may be channeled to regulate the 
actions of nursing home facilities as well.  Part IV addresses state common law doctrines of 
                                                         
7 Formerly known as the Health Care Financing Administration (HCFA).   3 
informed consent and the right to refuse treatment in several states, as well as the strengths and 
weaknesses of this system in relation to elderly nursing home residents.  Part V will suggest 
solutions to system failures via multi-faceted changes at federal and state levels in order to make 
the available framework more effective and coherent, as well as broader policy adjustments 
going forward in the future. Part VI concludes. 
II. Medical Issues 
Antipsychotic drug treatment for behavioral problems related to cognitive impairment in the 
elderly has become a pressing issue because of the prevalence of these symptoms in nursing 
facility residents.  More than 50 percent of residents in assisted living and nursing homes have 
some form of dementia or cognitive impairment, including Alzheimer’s disease.
8  Almost all 
patients with Alzheimer’s experience some degree of behavioral disturbance during the course of 
their disease, including depression, anxiety, apathy, psychosis and agitation.
9  These symptoms 
vary in frequency and severity and can present challenges for patients and caregivers.  
Traditionally, typical antipsychotics have been used to treat agitation and psychosis related to 
Alzheimer’s disease
10.  Although effective, these drugs cause increased risk of death and 
cardiovascular events, worsening of cognitive function, increased Parkinsonism,
11 metabolic 
disease, and falls.
12  Due to the changes occurring with age, prescribing drugs for the elderly is 
very different from prescribing for other members of society.
13  In addition to other mental 
                                                         
8 See Alzheimer’s Association, Alzheimer’s Association Releases Dementia Care Practice Recommendations for 
End-of-Life Care, available at http://www.alz.org/national/documents/release_082807_dcrecommends.pdf (last 
updated Aug. 28, 2007). 
9 See Sergio E. Starkstein et al., Apathy Predicts More Severe Parkinsonism in Alzheimer’s Disease, 17 AM. J. 
GERIAT. PSYCHIATRY 291, 292 (2009). 
10 See Gordon K. Wilcock, Treatment for Alzheimer’s Disease, 15 INT. J. GERIAT. PSYCHIATRY 562, 562 (2000). 
11 Symptoms similar to those exhibited with Parkinson’s disease, including tremor of resting muscles, rigidity, 
slowness of movement, impaired balance, and a shuffling gait.  See Starkstein, supra note 9.  
12 See Clive Ballard et al., A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or 
stopping Neuroleptics (The DART-AD Trial), 5 PLOS MEDICINE 587, 587 (2008). 
13 See James A. Jernigan, Update on Drugs and the Elderly, 29 AM. FAM. PHYSICIAN 238, 238 (1984).   4 
problems, depression is often attributable to elderly patients taking multiple drugs 
(polymedication) which complicate and worsen their conditions.
14  Prescribed judiciously, 
antipsychotic drugs can enhance the physical and psychological well-being of the elderly.  
However, altered drug disposition makes this age group particularly sensitive to the undesirable 
side effects discussed above, which can lead to a decline in medical and functional status of the 
patient and an increased risk of drug interactions.
15  Because of the many deleterious side effects 
of these drugs, the American Academy of Family Physicians recommends that antipsychotics 
only be used as a last resort in the management of behavioral problems in the elderly.
16   
The problem of overmedication and excessive use of antipsychotics in nursing facilities 
continues today despite the myriad legislative measures in the past two decades.  In 2009, an 
investigative report by the Chicago Tribune reviewing more than 40,000 federal and state 
inspection reports for Illinois' 742 nursing facilities identified 1200 violations involving 
antipsychotic medications and affecting 1900 residents since 2001.
17  The report identified 12 
resident deaths and dozens of incidents where residents broke bones after falling while they were 
medicated.
18  The recorded reasons for medication were tenuous: one resident was “yelling out” 
and “easily annoyed;" another resident was “teasing another resident and generally being 
'nasty.'"
19  Similarly, the Boston Globe reported that nearly 28% of all Massachusetts nursing 
                                                         
14 See Tina M. Champion, The Elderly Suing Doctors: Reasons and Recovery, 12 ALB. L.J. SCI. & TECH. 895, 900 
(2002). 
15 See Kiran Rabheru, Alternatives to Atypical Antipsychotics for the Management of Dementia-Related Agitation, 
25 DRUGS & AGING 381, 383 (2008). 
16 See Ann M. Hamer and John Muench, Adverse Effects of Antipsychotic Medications, 81 AM. FAMILY PHYSICIAN 
617, 621 (2010). 
17 See Sam Roe, Compromised Care: Psychotropic Drugs Given to Nursing Home Patients Without Cause. CHI. 
TRIB. (Oct. 27, 2009). 
18 See id. 
19 See id.   5 
home residents were given antipsychotic drugs in 2009 and that 22% of them (2483 residents) 
did not have a medical condition supporting use of the drug.
20 
Misuse of antipsychotic medications in the treatment or control of nursing home residents is 
still pervasive, despite the development of suitable alternatives to the use of chemical and 
physical restraints.
21 In fact, studies performed in the early 1990s indicated that lower rates of 
restraint use appear to have been achieved with no increase in serious resident injuries, economic 
costs, or legal liability exposure for the nursing facility.
22 When restraints have been removed 
and independence and rehabilitation are encouraged as an alternative, the ability of residents to 
perform daily activities improves.
23  Despite these findings, in 2009, 26.1% of the nation’s 
1,359,787 nursing home residents still received antipsychotic drugs,
24 frequently for reasons not 
approved by the FDA.
25 
 
III. Federal Legislation 
A. OBRA ‘87 
Congress devised several solutions to the problem of overmedication with antipsychotic 
drugs in nursing facilities in the past, beginning with an amendment to the Older Americans Act 
                                                         
20 See Kay Lazar, Nursing Home Drug Use Puts Many at Risk, BOSTON GLOBE, Mar. 8, 2010. 
21 See Joan M. Dunbar et al., Don’t Restrain: The Education Intervention of the National Nursing Home Restraint 
Removal Project, 36 GERONTOLOGIST 539 (1996); Perla Werner et al., Individualized Care Alternatives Used n the 
Process of Removing Physical Restraints in the Nursing Home, 42 J. AM. GERIATRICS SOC’Y 321 (1994). 
22 See e.g., Mary E. Tinetti et al., Mechanical Restraint Use and Fall-related Injuries among Residents of Skilled 
Nursing Facilities, 116 ANNALS INTERN. MED. 369 (1992); Charles D. Phillips et al., Reducing the Use of Physical 
Restraints in Nursing Homes: Will It Increase Costs? 83 AM. J. PUB. HEALTH 342 (1993); Marshall B. Kapp, 
Restraint Reduction and Legal Risk Management, 47 J. AM. GERIATRICS SOC’Y 375 (1999). 
23 See, e.g., Richard R. Neufeld & Joan M. Dunbar, Restraint Reduction: Where Are We Now? NURSING HOME 
ECON., May-June 1997, at 11, 12 (arguing that the ability of residents to participate in daily activities improves 
when restraints are removed). 
24 See CMS, MDS Active Resident Information Report: Fourth Quarter 2009, Medications- Days Received the 
Following Medication – Antipsychotic, available at 
http://www.cms.gov/MDSPubQIandResRep/04_activeresreport.asp?isSubmitted=res3&var=O4a&date=29 (last 
visited Mar. 30, 2011). 
25 See Center for Medicare Advocacy, Inc., Off-Label Drug Use Is Common and Hurts Nursing Home Residents, 
available at http://www.medicareadvocacy.org/2010/03/off-label-drug-use-is-common-and-hurts-nursing-home-
residents/ (last visit Mar. 30, 2011).   6 
of 1965 which made state receipt of federal funds under Title III of the Act contingent upon the 
state’s establishment and adherence to a comprehensive plan in compliance with the Act.
26 Most 
significantly, Congress incorporated another solution in the Omnibus Budget Reconciliation Act 
of 1987 (OBRA ’87).
27  OBRA ’87 included extensive revisions to the statutory Medicare and 
Medicaid requirements for long-term care facilities, including limiting the use of antipsychotic 
medications for residents.   
The final rules for the application of OBRA ’87 promulgated by the Department of Health 
and Human Services (HHS) in 1991 raised expectations of sweeping reform in the nursing home 
industry.  These rules included implementation of Congressional intent to protect the rights of 
nursing home residents to freedom from “any physical or chemical restraints imposed for 
purposes of discipline or convenience.”
28  The regulations clarify that freedom from restraint also 
encompasses the resident’s right to refuse treatment.
29  Restraints may only be imposed under a 
physician’s order to treat the resident’s medical problems after less restrictive or intrusive 
interventions have been considered and attempted unsuccessfully, rather than for the purpose of 
discipline or staff convenience.
30  Similar provisions restricting the permissible scope of physical 
and chemical restraints appear in the “Resident Bill of Rights” adopted by each state.
31  Although 
one section of the act sets out minimum “quality of life” standards, requiring that each facility 
“must provide a safe, clean, comfortable and homelike environment,”
32 these standards fail to 
cover the decrease in quality of life caused by overmedication and lower functioning associated 
with antipsychotic drugs.   
                                                         
26 See 42 U.S.C. § 3021(c) (1990). 
27 See The Omnibus Budget Reconciliation Act of 1987, Pub. L. 100-203, 101 Stat. 1330-275. 
28 42 U.S.C. §1395i-3(c)(1)(A)(ii)(2000).   
29 42 C.R.R. §483.10(b)(4)(2003). 
30 42 C.F.R. §483.13(a)(2000); 42 U.S.C.A. §1395i-3(c)(1)(A)(ii); 1396r(c)(1)(A)(ii). 
31 See Don’t Make Them Leave Their Rights at the Door: A Recommended Model State Statute to Protect the rights 
of the Elderly in Nursing Homes, 4 CONTEMP. HEALTH L. & POL’Y 321, 322 (1988). 
32 See 42 C.F.R. §483.15(b)(1)(2003).   7 
Although the Federal Nursing Home Reform Amendments (FNHRA), attached to OBRA 
’87, do not explicitly give a private right of action, such a right is essential to the effectiveness of 
the statute.  Although CMS performs annual inspections of facilities receiving Medicare or 
Medicaid funding,
33 these visits are insufficient to capture an accurate account of the more subtle 
issues of overmedication.
34  However, a private right of action would allow patients and their 
families, parties better situated than CMS to observe negligent and purposeful overuse of 
antipsychotics, to bring suit and hold nursing facilities liable.  The Third Circuit has ruled that 
the Act does in fact implicitly give nursing home residents the right to bring claims to challenge 
the quality of their treatment, although other jurisdictions have yet to follow the Court’s lead. 
35   
In Grammer v. John J. Kane Regional Centers- Glen Hazel, the Third Circuit held that "language 
used throughout the FNHRA is explicitly and unambiguously rights-creating."
36  The Court 
reasoned that federal laws that do not explicitly authorize private causes of action may do so 
implicitly and furthermore, actions for violations of federal law under 42 U.S.C. § 1983 are 
“presumptively available” against individuals acting under color of state law.
37  Congress should 
codify this judicially created private right of action as an amendment to the Act in order to give 
                                                         
33 “CMS may conduct an onsite inspection of the accreditation organization's operations and offices to verify the 
organization's representations and to assess the organization's compliance with its own policies and procedures.” 42 
C.F.R. §488.9. 
34 U.S. Government Accountability Office (GAO) identified procedural weaknesses and predictable timing of state 
surveys of nursing homes as leading to understatements of the extent of serious care problems by state surveyors.  
Nursing Home Quality: Prevalence of Serious Problems, While Declining, Reinforces Importance of Enhanced 
Oversight. Report to Congressional Requesters (statement of William J. Scanlon, Director, Health Financing and 
Public Issues, Health, Education and Human Services Division) (published as GAO-03-561) available at 
http://www.google.com/url?sa=t&source=web&cd=1&sqi=2&ved=0CBgQFjAA&url=http%3A%2F%2Fwww.gao.
gov%2Fnew.items%2Fd03561.pdf&rct=j&q=gao%20nursing%20home%20quality&ei=eF-XTc3-HsmE0QHF--
j1Cw&usg=AFQjCNGI7yQGM9M0dxaATWIf-Dt6ON4qww&sig2=ueNYxle5n59X99uwGkD5dQ. 
35 See, e.g., Duncan v. Johnson-Mathers Health Care, Inc., 2010 WL 3000718 (E.D. Ky Jul. 28, 2010) (NO. 5:09-
CV-00417-KKC) (holding that the statute’s focus is on nursing homes, not the nursing home residents, and therefore 
an implicit private right of action should not be construed in the statutory language). 
36 570 F.3d 520, 532 (3
rd Cir. 2009). 
37 See id. (citing Livadas v. Bradshaw, 512 U.S. 107 (1994)).   8 
all nursing home residents and their families the ability to make full use of this act in preventing 
the unnecessary prescription of risky antipsychotics. 
B. CMS Guidelines 
The Centers for Medicare and Medicare Services (CMS), the agency responsible for 
regulating nursing homes participating in the Medicare and Medicaid programs, developed 
interpretive guidelines for fulfilling OBRA requirements which were implemented nationally in 
1990.
38  All antipsychotic drugs are subject to the “unnecessary drug” regulation of OBRA.  
According to the CMS guidelines, “residents must be free of unnecessary drugs” which are 
defined as those that are “duplicative, excessive in dose or duration, or used in the presence of 
adverse effects or without adequate monitoring or indication.”
39  Medical, environmental and 
psychosocial causes of behavioral problems must be ruled out, and nonpharmacologic 
management must be attempted before antipsychotic drugs are prescribed to nursing home 
residents.
40  Because treatment with antipsychotic medications is indicated only to maintain or 
improve functional status, diagnoses and specific target symptoms or behaviors must be 
documented and the effectiveness of drug therapy must be monitored.
41   
Each nursing home is surveyed annually to ascertain compliance with OBRA and CMS 
guidelines.
42  Because facilities that do not meet CMS’s legislated requirements may be denied 
Medicare reimbursement, physicians who prescribe medications for nursing home residents must 
document the medical necessity of noncompliance with regulations.
43  As a resource for 
physicians and facilities, a local consultant pharmacist reviews all charts monthly and assists 
                                                         
38 See Health Care Financing Administration.  Survey procedures and interpretive guidelines for skilled nursing 
facilities and intermediate care facilities.  Baltimore: U.S. Dept. of Health and Human Services, 1990. 
39 42 C.F.R. §483.25. 
40 See id. 
41 See id. 
42 See id. 
43 See id.   9 
with compliance.
44 According to the OBRA strategy, the long-term care facility, rather than the 
prescribing physician, is accountable for monitoring drug use.  This approach reflects the 
realities of nursing home practice, because the prescribing physician only visits the facility 
occasionally.
45  Despite CMS and state survey activities, weaknesses persist in identifying 
nursing facility quality-of-care issues.  Poor investigation and documentation of deficiencies, 
limited quality assurance systems, and large number of inexperienced surveyors, as well as 
predictable survey timing allow nursing facilities to conceal problems from surveyors.
46  
Although CMS is working to improve state survey review, federal and state reforms are still 
poorly balanced and violations by nursing homes continue.  More legislative fine-tuning must be 
undertaken if the elderly in resident care are to be guaranteed protection of their rights.   
C. FDA Regulation  
1. Off-Label Use 
Along with CMS regulation of resident patient care in nursing facilities, the Food and Drug 
Administration (FDA) also plays a role in regulating antipsychotic treatment.  Under the heading 
of “off-label use,” the FDA allows physicians to use available drugs for indications that are not 
included in approved labeling without submission of a new drug application.
47  Off-label 
                                                         
44 See id. 
45 See Rebecca Dresser, The Curious Case of Off-Label Use, 37 HASTINGS CTR. REP. 9, 9 (2007). 
46 See Nursing Home Quality: Prevalence of Serious Problems, While Declining, Reinforces Importance of 
Enhanced Oversight. Report to Congressional Requesters (statement of William J. Scanlon, Director, Health 
Financing and Public Issues, Health, Education and Human Services Division) (published as GAO-03-561) 
available at 
http://www.google.com/url?sa=t&source=web&cd=1&sqi=2&ved=0CBgQFjAA&url=http%3A%2F%2Fwww.gao.
gov%2Fnew.items%2Fd03561.pdf&rct=j&q=gao%20nursing%20home%20quality&ei=eF-XTc3-HsmE0QHF--
j1Cw&usg=AFQjCNGI7yQGM9M0dxaATWIf-Dt6ON4qww&sig2=ueNYxle5n59X99uwGkD5dQ. 
47As long as the physician is well informed about the product and bases the use on firm scientific rationale and 
sound medical evidence when the intent is the “practice of medicine” without submission of an Investigational New 
Drug Application (IND), Investigation Device Exemption (IDE) or review by an Institutional Review Board (IRB). 
See U.S. Food and Drug Administration, “Off-Label” and Investigational Use of Marketed Drugs, Biologics, and 
Medical Devices – Information Sheet, available at 
http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm  (last updated Oct. 18, 2010).   10 
prescriptions are widely used, and comprise approximately 21% of drug use overall.
48  There are 
three primary types of off-label use: (1) using a drug to treat a condition for which it is not 
indicated, (2) treating an indicated condition with different doses than those specified on the 
label, and (3) prescribing a drug for a different patient population than that indicated.
49  Off-label 
uses of approved medications have not been subjected to the baseline FDA scrutiny required for 
on-label indications, and are therefore considered riskier.
50  FDA approved primary indicated 
uses for antipsychotic drugs include treatment of schizophrenia and bipolar disorder.
51  
Treatment for dementia in the elderly is one common off-label use of antipsychotics.
52   
Under the Food, Drug, and Cosmetic Act, a drug is misbranded when its labeling does not 
contain “adequate directions for use.”
53  The FDA cannot approve adequate directions for use 
until the drug is approved for a particular use or indication based on the FDA’s finding that the 
drug is safe and effective.
54  A drug that is promoted for an unapproved (off-label) indication or 
use does not contain “adequate directions for use” because the off-label indication or use is not 
included in the FDA-approved labeling for the drug.  Thus a manufacturer’s promotion of a drug 
for an off-label use constitutes misbranding of the drug.
55  Although it is improper for a drug 
company to affirmatively merchandize a drug for an off-label use, doctors may voluntarily 
                                                         
48 Anna Wilde Mathews & Avery Johnson, FDA to Propose Guidelines for ‘Off-Label’ Drug Use, WALL ST. J. (Feb. 
15, 2008). 
49 See U.S. Food and Drug Administration, “Off-Label” and Investigational Use of Marketed Drugs, Biologics, and 
Medical Devices – Information Sheet, available at 
http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm  (last updated Oct. 18, 2010). 
50 See id. 
51 See e.g., Label approved on Mar. 1, 2011 for Haldol, NDA no. 015923. U.S. Food and Drug Administration, FDA 
Approved Drug Products: Label and Approval History, available at 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s086,018701s063lbl.pdf (last visited Mar. 30, 
2011). 
52 Other off-label uses for antipsychotics included treatment of symptoms related to agitation, anxiety, psychotic 
episodes, obsessive behavior, and behaviors related to dementia and depression. See Marisa E Domino & Marvin S. 
Swartz, Who Are the New Users of Antipsychotic Medications? 59 PSYCHIATR SERV 507, 511 (2008). 
53 21 U.S.C. §352(f)(1). 
54 21 U.S.C. §§352,355(a),(d). 
55 See In re Zyprexa Products Liability Litigation, 671 F.Supp.2d 397, 414-5 (E.D.N.Y. 2009).   11 
prescribe FDA approved medicines for approved and unapproved uses as they deem appropriate 
in their professional judgment.
56   
2. Black Box Warnings 
In addition to its authority to prosecute the misbranding of drugs, the FDA was also given the 
authority to mandate drug warnings by the Food and Drug Administration Amendments Act 
(FDAAA) of 2007.
57  Previously, the FDA could only request, but not require that the 
manufacturer comply with suggested drug warning labeling.
58  An FDA black box warning is 
ordinarily issued to highlight that there is an adverse reaction
59 sufficiently serious in proportion 
to the potential benefit from the drug such that it is essential to be considered in assessing the 
risks and benefits of using that drug.
60 Such warning has been issued for all antipsychotics used 
to treat the elderly in nursing facilities.
61  No antipsychotics have been approved by the FDA for 
treating psychosis or agitation in elderly patients with dementia
62.  However, the black-box 
warning is not a contraindication and clinicians still have the option of using these drugs for 
dementia patients at their discretion.
63 The focus of the warning was to make physicians aware of 
the risks of treatment in order to sufficiently inform patients and caregivers of the risks.
64   
                                                         
56 See id.  
57 See Food and Drug Administration Amendments Act of 2007, Pub.L. 110-85, §1, Sept. 7, 2007, 121 Stat. 823. 
58 See id. 
59 The FDA defines serious adverse reaction as fatal, life-threatening or permanently disabling.  Food and Drug 
Administration, Guidance for Industry: Warnings and Precautions, Contraindications, and Boxed Warning Sections 
of Labeling for Human Prescription Drug and Biological Products – Content and Format, available at 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075096.pdf (last 
updated Jan. 17, 2006). 
60 See id. 
61 See Food and Drug Administration, FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs, 
available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm (last updated 
June 16, 2008). 
62 See id.  
63See Jun Yan. FDA Extends Black-Box Warning to All Antipsychotics, 43 PSYCHIATRIC NEWS 1, 1 (2008). 
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The FDA issued the black box warnings for antipsychotics in response to approximately 
15,000 elderly nursing home residents dying each year from the off-label use of antipsychotic 
drugs for “an indication [for which] FDA knows the drug doesn't work."
65  A retrospective 
analysis of the use of anti-psychotic drugs by Medicare beneficiaries in nursing homes in 2000-
2001 found the highest rate of antipsychotic drug use in more than a decade.
66  More than a 
quarter of residents received at least one prescription for antipsychotic drugs and of those, more 
than half took doses exceeding maximum levels, received duplicative therapy, or had 
inappropriate indications according to guideline requirements.
67  The atypical antipsychotic 
drugs were inappropriately used for residents with depression, dementia, and nonaggressive 
behavior problems.  Resident outcomes did not improve with use of the atypical 
antipsychotics.
68   
In response to these statistics, in 2005, the FDA first issued black box warnings against 
prescribing atypical antipsychotic drugs for patients with dementia which indicated that the drugs 
increased dementia patient mortality.
69  In June 2008, the FDA extended its warning to all 
categories of antipsychotic drugs and explicitly advised health care professionals that 
"[a]ntipsychotics are not indicated for the treatment of dementia-related psychosis."
70 Although 
the FDA's black box warning led to some decrease in the use of antipsychotics for elderly 
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patients with dementia,
71  more than 29% of newly-admitted residents nursing home residents 
who were admitted in 2006, after the first black box warning was issued, still received at least 
one antipsychotic medication that year, more than a third of whom had no identified clinical 
indication for antipsychotic drug therapy.
72   The percentage of nursing home residents who 
continue to be treated with antipsychotics off-label indicates that black box warnings standing 
alone are insufficient to address the problem of over-prescription.     
3. Pharmaceutical Company Litigation 
The extensive use of atypical antipsychotic drugs for nursing home residents may in part be 
attributed to drug companies' marketing of such off-label uses for residents, as reflected in recent 
litigation by the United States against drug companies for misbranding antipsychotic drugs.  
Litigation centered on the atypical antipsychotic drug Zyprexa,
73 manufactured by Eli Lilly and 
indicated for use in patients with schizophrenia and bipolar disorder.
74  The FDA has never 
approved Zyprexa for treatment of dementia in the elderly.  Zyprexa’s current label bears an 
FDA-mandated black box warning that “Elderly patients with dementia-related psychosis treated 
with antipsychotic drugs are at an increased risk of death.  Zyprexa is not approved for the 
treatment of patients with dementia-related psychosis.”
75  Between September 1999 and 
November 2003, Eli Lilly’s long-term care sales force promoted Zyprexa for the treatment of 
dementia, depression, anxiety, and sleep problems in nursing home residents, despite the lack of 
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FDA approval for those uses.
76  In January 2009, Eli Lilly pleaded guilty to a charge that it 
illegally marketed the anti-psychotic drug Zyprexa for an unapproved use and agreed to pay 
$1.42 billion to settle civil suits and end the criminal investigation.
77   
Eli Lilly’s promotion of Zyprexa for these additional intended uses violated 21 U.S.C. 
§352(f)(1) because Zyprexa’s labeling did not bear adequate directions for each of the drug’s 
intended uses.
78 In addition to the government charges for misbranding, over 30,000 cases were 
brought against Eli Lilly by individual plaintiffs suffering from serious psychiatric problems who 
were treated with Zyprexa.
79  These plaintiffs alleged that they suffered deleterious side effects 
and that Eli Lilly misled them and their physicians about the likelihood of these side effects 
which prevented them from making an informed decision about their treatment.
80  Despite the 
incredibly large criminal and civil penalties accrued by Eli Lilly during the course of litigation 
and settlement, Eli Lilly received $36 billion in revenues for Zyprexa between 2000 and 2008, an 
amount more than 25 times the $1.42 billion in total penalties paid by the company.
81  As large 
as the penalties are for drug companies found promoting an off-label use of a drug, the fines are 
incredibly small in proportion with the companies’ annual revenue.  Pharmaceutical companies 
spend around $800 million to research and develop a new drug and in order to recoup the 
investment, the companies want doctors to prescribe their drugs as widely as possible.
82    In 
order to effectively prevent the over-prescription of antipsychotic drugs for off-label use, the 
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FDA must do more than simply toss speeding tickets at pharmaceutical companies.  The next 
step should be to use FDA authority to make liable not only the pharmaceutical company 
marketing antipsychotics to nursing facilities for dementia patients, but also the facilities 
themselves for prescribing this risky treatment for resident patients. This will facilitate 
development of a more coherent body of patient rights in which drug companies and nursing 
facilities are both responsible for the informed consent and appropriate treatment of nursing 
home residents. 
IV. Informed Consent Doctrine 
Federal legislation defers to state law to determine patient competence to make treatment 
decisions.  State law also determines the degree of process necessary to deprive a patient of these 
rights.
83  The applicability of OBRA ’87 to a specific resident refusing treatment is therefore 
contingent on whether the individual has been deemed competent to do so as a matter of state 
law.
84  For this reason, the common law right of informed consent and the related right to refuse 
unwanted medical treatment are crucial to safeguarding a patient’s civil rights.  The interaction 
between a physician and a patient is grounded in the concept of informed consent, which requires 
competence, knowledge, and voluntariness.
85 Informed consent combines the physician’s duty to 
disclose with a requirement that the consenting individual is capable of understanding the 
information presented.
86 
A. Patient must be competent in order to give informed consent. 
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A determination of competence must be made before the physician discloses information to 
the patient.  The competency question must be resolved before determining whether a duty of 
disclosure has been met, because if incompetent, a patient by definition lacks the ability to 
understand and make informed decisions on the knowledge disclosed, therefore making his 
consent invalid.  Components of competency include: (1) ability to communicate a decision, (2) 
ability to comprehend material information, (3) ability to understand the situation and its 
probable consequences, and (4) ability to use the information rationally to make an informed 
decision.
87  The competence inquiry includes a presumption of competence for patients 
accepting treatment. If a patient agrees with a physician’s treatment recommendations, courts 
rarely if ever question the competency of that patient.
88  However, such inquiries should instead 
include a rebuttable presumption of competence for patients refusing treatment when treatment 
includes drugs carrying an FDA black box warning for the relevant use.  The black box warning 
indicates that the particular medical intervention has questionable benefits in proportion to 
significant risks, and therefore the rational decision may very well be to refuse treatment.  The 
burden should instead be shifted to the defendant nursing facility to show patient incompetence 
in such cases.  This reframing of the competency analysis would serve to protect patients from 
unnecessary use of such risky treatments by easing their burden of proof as plaintiffs, thereby 
encouraging litigation against offending nursing facilities. 
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B. Patient must be provided with adequate knowledge of the risks and benefits of 
treatment in order to give informed consent. 
Once the patient is determined to be competent, the next inquiry looks to the content of the 
information the physician gives the patient with which to make his decision.  The knowledge 
requirement correlates with the physician duty of disclosure.  Consent is invalid when given 
without adequate knowledge of the risks and benefits related to a particular treatment.
89 In many 
states, a customary practice standard is employed to determine whether the disclosure of 
information by a physician was sufficient.
90  Under this standard, disclosure is mandatory unless 
it (1) does not fall within the customary practice of physicians or (2) would violate local or 
national medical standards.
91  In other states, the focus is on the physician’s perspective and 
judges the sufficiency of the disclosed information based on whether the physician acted as a 
reasonable physician would have acted under the circumstances.
92  The approach is problematic, 
however, because of the potential for abuse of discretion and threats to patient autonomy.
93  A 
majority of states now use the materiality standard, which instead considers what might be 
important to the decision maker, including risks that would be considered material to the patient 
in making treatment decisions.
94 
The scope of the duty to disclose becomes especially difficult to define when dealing with  
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mental illness.  The duty to disclose can be judged either from the physician’s perspective or the 
patient’s perspective.
95  Both formulations take into account the difficulty of disclosing every 
possible outcome in any given treatment and both recognize that the physician cannot be 
responsible for disclosing more than he knows.
96  The physician perspective standard provides a 
great deal of deference to the physician’s professional judgment in disclosure to patients.  One of 
the problems with this approach is that it allows physicians to refrain from disclosing 
information that might be relevant to a particular patient if it is not customary under the self-
imposed standards of the medical community.
97  With the significant risks imposed by treatment 
with antipsychotic medication, obtaining consent for treatment if all potential risks were 
disclosed would likely be incredibly difficult; therefore, it may be customary to disclose only the 
most life-threatening possibilities even though other possible effects might be material to patient 
decision-making.
98   
The patient-centered materiality standard is also problematic because it inadequately 
accounts for variability in symptoms of mental illness.  Information that may be deemed relevant 
by a “reasonably prudent patient” must be disclosed under this standard.
99  At first glance, this 
standard appears to require a more thorough exchange of information between physicians and 
patients.  However, “reasonable” behavior may differ not only for different mental illnesses and 
different proposed treatments but also for different individuals with the same illness.  Without a 
method by which to objectively measure disease severity for mental conditions, patients with 
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mental illnesses are less likely to receive the information they require relative to their level of 
impairment in order to make an informed decision regarding their treatment.
100 
C. Patient decision must be made voluntarily in order to be considered informed 
consent. 
The final requirement for judging whether a treatment decision was made with informed 
consent is that the decision be made voluntarily.
101  A decision is considered to be involuntary 
when “some element is involved that prevents an individual from acting freely.”
102  In order to 
establish coercion, a party must demonstrate that the patient gave consent which they would not 
have otherwise given had they not been under duress.
103  
V. Proposed Solutions 
In order to provide a solution to the lack of protection for a patient’s right to be free of 
unnecessary treatment with antipsychotics, adjustments to the existing regime are needed.  The 
multifaceted approach to regulation of patient care in nursing facilities in turn requires a 
multifaceted solution to its shortcomings.  First, at the federal level, Congress should follow the 
Third Circuit in Grammer v. Glen Hazel in reading a private right of action into OBRA ’87 and 
codify the private right of action so that patients may bring suit for violations of the Act as well 
under the state law duty to disclose.
104  Second, within the informed consent inquiry under state 
law, the burden of proof to show competency should be shifted to the defendant facility for 
instances in which the patient refuses treatment carrying a black box warning.  This will give 
teeth to the FDA-issued warnings, as well as ease the way for plaintiff patients to present their 
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case.  Third, once competency has been shown, the presence of a black box warning in the 
treatment regime should create a presumption of materiality of the risks disclosed on the label 
which therefore must be disclosed to the patient.  Fourth, liability for federal and state law 
violations should be shifted from nurses and physicians to nursing facilities in order to promote 
adequate staffing and alternatives to antipsychotic drug treatment.  Lastly, receipt of Medicare 
and Medicaid funding should be contingent upon the phasing in of requirements for emphasis on 
non-drug related behavioral treatment with increased personal care.  Such requirements could 
include mandatory training or an employee exchange program at facilities that currently employ 
such techniques, government grants to fund the upfront costs of implementing additional training 
and alternative therapies to be off-set by the reduction in spending on unnecessary drug 
treatment.  
A. Congress should create a private right of action under OBRA ’87. 
  Congress should follow the Third Circuit in Grammer v. Glen Hazel and create a private 
right of action into OBRA ’87 so that patients may bring suit for violations of the Act as well 
under the state law duty to disclose.  As the Court noted in Grammer, the Federal Nursing Home 
Reform Acts (FNHRA) are “replete with rights-creating language.”
105  The amendments confer 
upon nursing home residents the right to choose their personal attending physicians, to be fully 
informed about and to participate in their treatment, to be free from abuse and to voice 
grievances and to enjoy privacy and confidentiality.
106  Nursing homes are required to care for 
residents in a manner promoting quality of life and provide services and activities to maintain the 
highest practicable physical and mental well-being of residents.
107  The statue also specifically 
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guarantees nursing home residents the right to be free from chemical restraints imposed for the 
purposes of discipline or convenience and not required to treat their medical symptoms.
108  
However, only a small minority of states have created greater protection for nursing home 
residents through legislation that imposes liability on facilities for violation of regulations.
109  
Attorney’s fees and the cost of litigation alone can prevent residents from pursuing a claim 
against a nursing home.  By creating a statutory cause of action for violations of regulatory 
standards, the need to establish the standard of care and its violation is simplified and may 
reduce litigation costs for potential plaintiffs.  This in turn may increase nursing facility 
compliance with the FNHRA and ensure more effective protection for the patient rights specified 
in the legislation. 
B. Burden of proof in competency inquiry should be shifted from patient to 
defendant facility. 
Under the state law doctrine of informed consent, the burden of proof to show patient 
competency should be shifted to the defendant facility for instances in which the patient refuses 
treatment carrying a black box warning.  This will give teeth to the FDA-issued warnings, as 
well as ease the way for plaintiff patients to present their case.  As discussed above, 
determination of competence should be made prior to disclosure of information.
110  The 
competency question must be resolved before determining whether a duty of disclosure has been 
met, because if incompetent, a patient by definition lacks the ability to logically understand and 
incorporate the knowledge disclosed, therefore making his consent invalid.  Currently, the 
competency inquiry includes a presumption of competence for patients accepting treatment.  
However, such inquiries should instead include a rebuttable presumption of competence for 
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patients refusing treatment when treatment includes drugs carrying an FDA black box warning 
for the relevant use.  Such reframing of the competency analysis would serve to protect patients 
from unnecessary use of such risky treatments.  If OBRA ’87 provided an explicit right to 
nursing home residents to refuse medication in all but the most extreme cases, the result would 
be a uniformly high standard.  This might tie the hands of physicians to effectively treat patients, 
and possibly cause delays in treatment and lower quality of care in nursing facilities because 
doctors would not want to risk the increased liability of treating resident patients.  However, 
creating a rebuttable presumption of competency for refusal of medication carrying black box 
warnings is a more narrowly tailored heightening of the standard and would avoid many of 
problems of a uniformly high standard. 
C. Risks indicated in a black box warning should be presumed material to patient 
decision-making under the knowledge inquiry. 
As discussed above, under the informed consent doctrine, the physician has a duty to disclose 
information material to the patient’s decision-making process.
111  Consent is only considered 
informed when the patient is given adequate knowledge of the material risks and benefits of the 
proposed treatment.   The materiality standard considers what might be important to the 
decision-making patient, including risk that would be considered material to the patient in 
determining whether the proposed treatment should be undertaken.
112  The presence of an FDA 
black box warning in the treatment regimen should create a presumption that the risks disclosed 
on the label are material and therefore must be disclosed to the patient.   
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In promoting off-label use of drugs, pharmaceutical companies often reward physicians to 
incentivize prescribing their drugs.
113  Because the FDA has no authority to regulate physician 
prescription of drugs for off-label uses, patient rights are left in the hands of the informed 
consent doctrine under state law for protection.  However, most doctors do not keep track of 
FDA-approved drug uses.
114  Therefore, in order to give teeth to FDA regulation in this area, 
state law informed consent doctrine should incorporate FDA regulations in order to target both 
drug company promotion and physician prescribing practices.  If the risks disclosed in the FDA 
black box warning on the label are presumed material, the defendant nursing facility will not be 
able to show informed consent if the patient has not been informed about these risks before 
agreeing to treatment.  Under this doctrine, even though the FDA has no authority over 
physicians, pharmaceutical companies will no longer be as successful in getting physicians to 
prescribe drugs with black box warnings for off-label uses because the physicians will be 
required to inform the patients of the risks listed on the warning.  The physician community will 
have to take responsibility to perform their own due diligence about a drug beyond the 
information they receive from a pharmaceutical representative.  However, this doctrine would 
still allow physicians to use their professional judgment without undue judicial interference. 
D. Liability should be shifted from nurses to the nursing facility in order to facilitate 
non-drug related treatment. 
Situations often occur in which a nursing home is understaffed and the nursing home is 
unable or unwilling to alleviate the situation for the nurses working the facility.  The availability 
of additional care should be incentivized both positively, in the form of tax breaks and 
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reimbursement benefits, as well as negatively, by shifting liability from the nurses and treating 
physicians to the nursing home facility itself if the facility does not provide sufficient staffing to 
allow alternate treatments to be available to patients suffering from behavioral problems 
associated with dementia.  Reducing nurse stress from understaffing will also increase focus and 
quality of care.
115  Although nursing homes are required to maintain “sufficient nursing staff to 
provide nursing and related services to attain or maintain the highest practicable physical, 
mental, and psychological well-being of each resident,” no specific number of required staff 
members is stated.
116  This ambiguity allows nursing homes to continue to understaff their 
facilities.
117 Additional nursing facility liability for proximately caused injuries by an employee 
or the facility itself would focus on the institution and the way it operates instead of on 
individual nurses and physicians.  This would also incentivize residents and their families to act 
as private attorneys general in prosecuting nursing facility violations.  Such litigation would 
create a larger potential cost for understaffing, which would in turn incentivize nursing facilities 
to provide adequate staffing in order to avoid litigation costs.  Nurses working in adequately 
staffed facilities with a reduced threat of litigation against them as individual parties may be less 
likely to favor antipsychotic drug therapy in response to behavioral problems, a quick-fix but 
problematic method of treatment, and instead begin to shift towards personal care. 
E. Receipt of Medicare and Medicaid funding should be contingent upon the 
phasing in of requirements for emphasis on non-drug related treatment. 
Antipsychotic drugs are still overused in long-term care, and become perpetualized to 
treat behaviors associated with dementia.  Although powerful cocktails of antipsychotic drugs 
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have become the standard of care for nursing home patients with unmanageable behavior, some 
nursing homes use alternative treatments that focus instead on intensive staff training to mitigate 
resident dementia-related behavioral problems.  Ecumen’s Awakenings project in Minnesota is 
one example of nursing homes that have embraced this approach.
118  The facility trains its entire 
staff to use tools to calm and reassure residents through exercise, music, massage, and 
aromatherapy without resorting to pharmacological intervention.
119  Despite the availability of 
this treatment option, nursing homes continue to rely on drug treatments because the alternative 
is both labor-intensive and expensive.
120 In spite of these drawbacks, the program enabled every 
resident on antipsychotics to discontinue treatment, and almost half of patients taking 
antidepressants were able discontinue medication as well.
121  
In light of the success of the Ecumen Awakenings project, alternative treatment options 
should be incentivized for all federally funded nursing facilities.  However, mere education about 
reducing antipsychotic drug prescribing for nursing home patients is not enough to reduce this 
practice.
122  Medicare and Medicaid funding should be made contingent upon the recipient 
facility shifting treatment emphasis to alternative, nonpharmacologic care in order to ensure 
action.  Although the government may have to provide subsidies at the onset in order to assist 
nursing facilities in the transition, these costs would be offset by the resulting decrease in 
national spending on medication. Currently, one in four nursing home residents receives 
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antipsychotic drugs, with sales in 2007 totaling over $13 billion.
123  The dramatic rise in the costs 
of prescription drugs over the past decade is in large part due to second generation 
antipsychotics, which now make up a substantial proportion of increased national spending on 
medication.
124  Because many patients treated with antipsychotics are severely disabled, 
Medicare and Medicaid are the largest buyers of the drugs.
125   If the care-centered non-
pharmacologic approach can successfully reduce nursing facility dependence on antipsychotics 
to control resident behavioral problems, then the costs to government programs will significantly 
decrease.
126  The difference in patient quality of life under a non-drug treatment regimen is 
incredibly significant, and the national government should take affirmative steps to achieve these 
results in every nursing facility in America.  
VI. Conclusion 
The current framework in place to protect nursing home patient rights is complex and yet full 
of gaps which have allowed nursing facilities to continue to overprescribe risky antipsychotic 
drugs for dementia-related behavioral problems. The tools with which to correct this problem are 
already provided in OBRA ’87, in the FDA’s regulatory authority, and in the state law doctrine 
of informed consent.  However, under the current regime, these bodies of law fit disjointedly.  
The adjustments to the existing system suggested by this paper are meant to develop coherence 
between these bodies of law in order to strengthen them into a single unified approach to 
protecting patient rights.  All of these steps are means to an end in which nursing facilities are 
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sufficiently staffed with trained care providers able to address resident behavioral problems with 
personal care to calm and reassure residents, instead of overmedicating them into a barely 
cognizant haze.  A shift away from overmedicating with antipsychotics in nursing home patient 
care will both stem the dramatic rise in national spending on prescription drugs as well as 
increase the quality of life for the elderly.   
 